Vaxil Bio, a leading developer of immunotherapeutic products to treat cancer and infectious diseases, reports today that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of Multiple Myeloma (MM), a blood cancer.

See the original post:
Vaxil Bio’s ImMucin receives EMA orphan drug designation for treatment of Multiple Myeloma

Scroll to Top